Company / Shareholders' Equity
Arcutis Biotherapeutics, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$189.5M
FY2025
5-year range
$88.7M / $297.7M
FY2021-FY2025
Trend
+20.3%
vs FY2024
Sector context
#156 of 213
Health Care
What the data says
At $189M, Arcutis Biotherapeutics, Inc.'s shareholders' equity ranks #156 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 8 years, ranging from -$65M in FY2019 to $298M in FY2021.
Based on SEC 10-K filings.
$189M in FY2025 with a 5-year CAGR of -6.9%.
Improved from $89M to $189M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -3.3%
- 5-Year CAGR
- -6.9%
- 10-Year CAGR
- -
Sector benchmark
#156 of 213 in Health CareTop 73% of 213This company $189.5M Sector average $2.5B
▼
-92.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -6.9%, indicating a declining trend.
- In FY2025, shareholders' equity increased 20.3% year-over-year.
- Ranks #156 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $189.5M | +20.3% |
| FY2024 | $157.5M | +77.7% |
| FY2023 | $88.7M | -57.7% |
| FY2022 | $209.6M | -29.6% |
| FY2021 | $297.7M | +10.0% |
| FY2020 | $270.6M | +516.2% |
| FY2019 | -$65.0M | -171.1% |
| FY2018 | -$24.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026